Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections

Antimicrobial Agents and Chemotherapy(2023)10.1128/aac.01655-22Source: DataRank Database

Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections is a research paper published in Antimicrobial Agents and Chemotherapy (2023). On theSindex it has a DataRank of 0. It has been cited 25 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access25 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 4.30)OA: hybridTopics (32)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Wassihun Wedajo Aragaw ORCID,Julianna Cangialosi,Véronique Dartois ORCID,Thomas Dick ORCID,Dereje A. Negatu ORCID

Live enrichment

PubMed:36920191 PMC:PMC10112060 OpenAlex:https://openalex.org/W4324311192

HHS | NIH | National Institute of Allergy and Infectious Diseases

Grant: R01 AI132374

HHS | NIH | National Institute of Allergy and Infectious Diseases

Grant: U19 AI142731

National Institutes of Health

Grant: 5U19AI142731-03

Center to develop innovative therapeutics to multidrug resistant high-threat bacterial agents

National Institutes of Health

Grant: 7R01AI132374-03

Combatting natural resistance and persistence in non-TB mycobacterial disease

FWCI

4.30

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://journals.asm.org/doi/pdf/10.1128/aac.01655-22?download=true

publisherhttps://journals.asm.org/doi/pdf/10.1128/aac.01655-22?download=true

publisherhttps://journals.asm.org/doi/pdf/10.1128/aac.01655-22

journalhttps://doi.org/10.1128/aac.01655-22

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36920191

Fields of Study

Mycobacterium research and diagnosisTuberculosis Research and EpidemiologyInfectious Diseases and Tuberculosis0303 health sciences03 medical and health sciences

MeSH Terms

LinezolidAnti-Bacterial AgentsHumansMycobacterium Infections, NontuberculousNontuberculous MycobacteriaTuberculosisOxazolidinones

Keywords

LinezolidTuberculosisMycobacterium tuberculosisNontuberculous mycobacteriaMedicineMycobacteriumAntibioticsMicrobiologyBiologyStaphylococcus aureusBacteriaPathologyVancomycinOxazolidinoneMitochondrial ToxicityHumansMycobacterium Infections, NontuberculousClinical TherapeuticsOxazolidinonesAnti-Bacterial Agents

Sustainable Development Goals

SDG 0: Good health and well-being